Ionis Pharmaceuticals Inc (IONS)

09:23 AM

KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha

09:23 AM

07:55 AM

Is Ionis Pharmaceuticals Inc. a good long term investmentBreakthrough capital growth - Autocar Professional

07:55 AM

07:15 AM

TRYNGOLZA Receives EU CHMP Approval Recommendation for Rare Disease FCS Treatment | IONS Stock News - Stock Titan

07:15 AM

Jul 23, 2025

Ionis Pharmaceuticals Inc. Stock Analysis and ForecastRemarkably fast returns - jammulinksnews.com

Jul 23, 2025

Jul 23, 2025

Ionis Pharmaceuticals (IONS) Earnings Expected to Grow: Should You Buy? - Yahoo Finance

Jul 23, 2025

Jul 23, 2025

Ionis Pharmaceuticals founder Stanley Crooke on the fight against rare diseases - MSN

Jul 23, 2025

Jul 23, 2025

What analysts say about Ionis Pharmaceuticals Inc. stockRapid portfolio appreciation - Autocar Professional

Jul 23, 2025

Jul 23, 2025

What drives Ionis Pharmaceuticals Inc. stock priceHigh-profit trading signals - jammulinksnews.com

Jul 23, 2025

Jul 22, 2025

Lou Gehrig’s Disease Clinical, Companies, Therapeutic Assessment, Therapies, Treatment Algorithm, Pipeline Analysis | Ionis Pharmaceuticals, 1ST Biotherapeutics, Scholar Rock, Revalesio, QurAlis Corpo - Barchart.com

Jul 22, 2025

Jul 22, 2025

Pinning Down Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) P/S Is Difficult Right Now - 富途牛牛

Jul 22, 2025

Jul 21, 2025

Biogen to Highlight Scientific Progress Across Alzheimer’s Disease at the Alzheimer’s Association International Conference 2025 - GlobeNewswire Inc.

Jul 21, 2025

Jul 21, 2025

Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com

Jul 21, 2025

Jul 21, 2025

Ionis HAE drug shows strong results in switch study - Investing.com Australia

Jul 21, 2025

Jul 21, 2025

Phase 3 OASISplus data demonstrating benefit of donidalorsen for HAE patients who switched from other prophylactics published in JACI In Practice - Yahoo Finance

Jul 21, 2025

Jul 17, 2025

Global Motor Neuron Disease Treatment Market to Exhibit Substantial Growth at a CAGR of ~6% by 2032 | DelveInsight - Yahoo Finance

Jul 17, 2025

Jul 17, 2025

Hutchinson-Gilford Progeria Syndrome Market Driven - openPR.com

Jul 17, 2025

Jul 16, 2025

(IONS) Technical Data - news.stocktradersdaily.com

Jul 16, 2025

Jul 16, 2025

Ionis Pharmaceuticals to Host Q2 2025 Earnings Webcast on July 30th - AInvest

Jul 16, 2025

Jul 16, 2025

Ionis to hold second quarter 2025 financial results webcast - Business Wire

Jul 16, 2025

Jul 16, 2025

Ionis To Hold Second Quarter 2025 Financial Results Webcast - Barchart.com

Jul 16, 2025

Jul 15, 2025

Ionis Pharma CEO Monia sells $48,416 in stock By Investing.com - Investing.com Canada

Jul 15, 2025

Jul 15, 2025

Ionis Pharmaceuticals CEO Monia Brett Sells 1160 Shares at $41.74 - AInvest

Jul 15, 2025

Jul 14, 2025

Multiple System Atrophy Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - The Globe and Mail

Jul 14, 2025

Jul 14, 2025

Spinocerebellar Ataxias Pipeline 2025: MOA, ROA, and Clinical Trial Insights Explored by DelveInsight | Biogen Inc, BioXcel Corp, Celavie Biosciences, Ionis Pharma, Anima Biotech Inc, Biohaven Pharma - Barchart.com

Jul 14, 2025

Jul 10, 2025

Barclays Upgrades Ionis Pharmaceuticals (IONS) Stock, Raises PT - Insider Monkey

Jul 10, 2025

Jul 09, 2025

11 Best Mid-cap Healthcare Stocks to Buy According to Hedge Funds - Insider Monkey

Jul 09, 2025

Jul 06, 2025

Ionis Pharmaceuticals’ SWOT analysis: stock outlook amid pipeline progress - Investing.com

Jul 06, 2025

Jul 06, 2025

Ionis (IONS) Announces Leadership Transition as R&D Veteran Richard Geary Prepares to Retire - MSN

Jul 06, 2025

Jul 04, 2025

Ionis Pharmaceuticals (IONS) Moves 9.1% Higher: Will This Strength Last? - MSN

Jul 04, 2025

Jul 04, 2025

Ionis' Tryngolza Cuts Triglyceride Levels in Late-Stage Study - MSN

Jul 04, 2025

Jul 03, 2025

Should You Buy Ionis Pharmaceuticals (IONS) After Golden Cross? - Zacks Investment Research

Jul 03, 2025

Jul 03, 2025

Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) Shares Climb 28% But Its Business Is Yet to Catch Up - simplywall.st

Jul 03, 2025

Jul 02, 2025

Ionis Pharmaceuticals Surges Amid Promising SMA Treatment Progress - StocksToTrade

Jul 02, 2025

Jul 02, 2025

Ionis Pharmaceuticals Advances as Barclays Upgrades Stock - timothysykes.com

Jul 02, 2025

Jul 02, 2025

Ionis Pharmaceuticals shares surge 8.89% intraday after Barclays analyst upgrades rating to 'Overweight'. - AInvest

Jul 02, 2025

Jul 01, 2025

10 Analysts Assess Ionis Pharmaceuticals: What You Need To Know - Nasdaq

Jul 01, 2025